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Abstract 
Background: We aimed to investigate the expression of proteins related with autotaxin (ATX)–lysophosphatidate 
(LPA) signaling and the clinical implications in primary and metastatic thyroid tumors.
Methods: We constructed tissue microarrays with 545 primary thyroid tumors [338 papillary thyroid carcinoma (PTC), 
111 follicular carcinoma (FC), 69 medullary carcinoma (MC), 23 poorly differentiated carcinoma (PDC), and four ana-
plastic carcinoma (AC)]. Immunohistochemical stains for proteins related to ATX–LPA signaling (e.g., ATX, LPA1, LPA2, 
and LPA3) were performed.
Results: The expression of ATX was highest in MC, while the LPA1 expression was higher in PDC and AC, and the 
expression of LPA2 and LPA3 was highest in PTC (p < 0.001). Additionally, the expression of ATX, LPA1, and LPA2 was 
higher in conventional-type PTC than in follicular-variant PTC (p < 0.05). PTC with BRAF V600E mutation showed higher 
expression of ATX, LPA1, LPA2, and LPA3 than PTC without BRAF V600E mutation (p < 0.001). In univariate analysis, ATX 
positivity (p = 0.005) and LPA1 positivity (p = 0.014) were correlated with shorter overall survival in PTC.
Conclusion: Proteins related to the ATX–LPA axis showed different levels of expression in primary thyroid tumors 
according to subtype.
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Background
Autotaxin (ATX) is a glycoprotein transcribed by 
the ENPP2 gene on chromosome 8 [1]. ATX is the 
same molecule as  lysophospholipase D and converts 
lysophosphatidylcholine (LPC) to bioactive lipid media-
tor lysophosphatidate (LPA). LPA, after binding to the 
appropriate receptor, activates phospholipase C and the 
MAPK, PI3K, and RhoA pathways and is involved in 
various cellular processes [2, 3]. LPA receptor is a G-pro-
tein-coupled receptor. There are at least six LPA recep-
tors, LPA1 through LPA6. LPA1 through LPA3 belong to 
the EGD family (i.e., LPA1-EDG2, LPA2-EDG4, LPA3-
EDG7), while LPA4 through LPA6 are similar to the 
P2Y nucleotide receptor [4]. This ATX–LPA signaling is 
involved in tumor formation, progression, and metastasis 
[5, 6].
Thyroid cancer is a relatively common malignancy, 
affecting about 1% of the population. The most com-
mon histologic type of thyroid cancer is papillary thy-
roid carcinoma (PTC), followed by follicular carcinoma 
(FC), medullary carcinoma (MC), poorly differentiated 
carcinoma (PDC), and anaplastic carcinoma (AC). These 
histologic subtypes of thyroid cancer are known to have 
different cell origins, clinical manifestations, metastatic 
patterns, and clinical prognoses. Previously, ATX has 
been reported to be highly expressed in undifferentiated 
carcinoma [7], and it is also indicated to be expressed in 
follicular carcinoma [8]. Furthermore, as ATX expression 
is higher in thyroid cancer than in benign lesion [9] and is 
correlated with prognostic factors in thyroid cancer [10], 
ATX–LPA signaling is likely to have an influence on thy-
roid cancer biology. However, studies on proteins related 
to ATX–LPA signaling in recurrent and metastatic thy-





2 Department of Pathology, Yonsei University College of Medicine, 
Severance Hospital, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, South 
Korea
Full list of author information is available at the end of the article
Page 2 of 9Shin and Koo  J Transl Med          (2019) 17:288 
not been reported. Thus, we aimed to assess the expres-
sion of proteins related to ATX–LPA signaling in recur-
rent and metastatic thyroid cancer and according to 
thyroid tumor subtype.
Materials and methods
Patient selection and histologic evaluation
Patients diagnosed with PTC who underwent surgery 
between January 2012 and December 2013 at Severance 
Hospital, Sinchon-dong, South Korea, were included in 
the study. As for the remaining subtypes, patients who 
underwent surgery between January 2000 and Decem-
ber 2014 at Severance Hospital were included. Those who 
had received preoperative chemotherapy were excluded. 
This study was approved by the Institutional Review 
Board of Yonsei University Severance Hospital. Hema-
toxylin-and-eosin-stained slides of all cases were retro-
spectively reviewed by a thyroid pathologist (Koo, JS). 
Clinicopathologic data were obtained from the patients’ 
medical records and included age at diagnosis, disease 
recurrence, metastasis, current status, and length of fol-
low-up. Tumor size, location (right or left lobe), extent 
(confined to the thyroid parenchyme or with extrathyroi-
dal spread), and number of metastatic lymph nodes were 
also noted from a review of the slides and the surgical 
pathology reports.
Tumor stroma of PTC was classified as follows: des-
moplastic type, tumor stroma composed of cellular 
fibroblast/myofibroblast proliferation; sclerotic type, 
tumor stroma composed of collagenous component with 
few cellular components; pauci type, near absence of a 
stromal reaction; or inflammatory type, tumor stroma 
composed of inflammatory cells such as lymphocytes.
Tissue microarray
A representative area showing tumor and tumor stroma 
was selected on a hematoxylin-and-eosin-stained slide, 
and a corresponding spot was marked on the surface of 
the paraffin block. Using a biopsy needle, the selected 
area was punched out, and a 3-mm tissue core was trans-
ferred to a 6 × 5 recipient block. Two tissue cores from 
the invasive tumors were extracted to minimize extrac-
tion bias. Each tissue core was assigned a unique tissue 
microarray location number that was linked to a database 
containing other clinicopathologic data.
Immunohistochemistry
The antibodies used for immunohistochemistry in this 
study are shown in Table  1. Formalin-fixed, paraffin-
embedded tissue sections were used for immunohisto-
chemistry. During the experiments, 3-μm-thick tissue 
sections were deparaffinized and rehydrated in xylene 
and graded alcohol. We used the Ventana Discovery XT 
automated stainer (Ventana Medical Systems, Tucson, 
AZ, USA). Cell Conditioning 1 buffer (citrate buffer, pH: 
6.0; Ventana Medical Systems, Tucson, AZ, USA) was 
used for antigen retrieval. Appropriate positive and nega-
tive controls were used for each antibody.
Interpretation of immunohistochemical staining
Immunohistochemical markers were assessed by light 
microscopy. All stained slides were semi-quantitatively 
Table 1 Expression of ATX–LPA axis-related proteins according to the histologic subtype of thyroid cancer
Italic values represent significance of p-value (p < 0.05)
PTC papillary thyroid carcinoma, FC follicular carcinoma, MC medullary carcinoma, PDC poorly differentiated carcinoma, AC anaplastic carcinoma
Parameters Total
n = 545 (%)
PTC
n = 338 (%)
FC
n = 111 (%)
MC
n = 69 (%)
PDC
n = 23 (%)
AC
n = 4 (%)
p-value
ATX < 0.001
 Negative 368 (67.5) 220 (65.1) 102 (91.9) 22 (31.9) 21 (91.3) 3 (75.0)
 Positive 177 (32.5) 118 (34.9) 9 (8.1) 47 (68.1) 2 (8.7) 1 (25.0)
LPA1 < 0.001
 Negative 292 (53.6) 169 (50.0) 73 (65.8) 44 (63.8) 5 (21.7) 1 (25.0)
 Positive 253 (46.4) 169 (50.0) 38 (34.2) 25 (36.2) 18 (78.3) 3 (75.0)
LPA1 (S) 0.051
 Negative 530 (97.2) 323 (95.6) 111 (100.0) 69 (100.0) 23 (100.0) 4 (100.0)
 Positive 15 (2.8) 15 (4.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
LPA2 < 0.001
 Negative 365 (67.0) 191 (56.5) 85 (76.6) 69 (100.0) 16 (69.6) 4 (100.0)
 Positive 180 (33.0) 147 (43.5) 26 (23.4) 0 (0.0) 7 (30.4) 0 (0.0)
LPA3 < 0.001
 Negative 189 (34.7) 56 (16.6) 52 (46.8) 67 (97.1) 10 (43.5) 4 (100.0)
 Positive 356 (65.3) 282 (83.4) 59 (53.2) 2 (2.9) 13 (56.5) 0 (0.0)
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evaluated [11]. Tumor and stromal cell staining was 
assessed as 0: negative or weak immunostaining in < 1% 
of the tumor/stroma; 1: focal expression in 1% to 10% of 
the tumor/stroma; 2: positive in 11% to 50% of the tumor/
stroma; or 3: positive in 51% to 100% of the  tumor/
stroma. Entire tumor areas included in the TMA were 
evaluated in all cases; a grade of 0 was considered nega-
tive and grades of 1 to 3 were considered positive.
Statistical analysis
Data were analyzed using Statistical Package for the 
Social Sciences for Windows, version 23.0 (SPSS Inc., 
Chicago, IL, USA). For determination of statistical sig-
nificance, Student’s t test and Fisher’s exact test were 
used for continuous and categorical variables, respec-
tively. When analyzing data with multiple comparisons, 
a corrected p-value with application of the Bonferroni 
multiple comparison procedure was used. Statistical 
significance was set at p < 0.05. Kaplan–Meier survival 
curves and log-rank statistics were employed to evaluate 
the time to tumor recurrence and overall survival. Multi-
variate regression analysis was performed using the Cox 
proportional hazards model.
Results
Basal characteristics of thyroid cancer
All retrieved cases were subject to this study, consisting 
of 338 cases of PTC, 111 cases of FC, 69 cases of MC, 23 
cases of PDC, and four cases of AC. Basal characteristics 
of PTC are listed in Additional file 1: Table S3. PTC cases 
were composed of 302 conventional type and 36 follicular 
variant, and 236 cases of PTC (69.8%) had BRAF V600E 
mutation. FC consisted of 61 cases of minimally invasive 
type, 37 cases of encapsulated angioinvasive type, and 13 
cases of widely invasive type (Additional file 1: Table S3). 
Basal characteristics of MC, PDC, and AC are listed in 
Additional file 1: Table S3.
Expression of proteins related to the ATX–LPA axis 
in thyroid cancer
The expression of proteins related to the ATX–LPA axis 
in thyroid cancer showed differences in ATX, LPA1, 
LPA2, and LPA3 (p < 0.001). ATX was most highly 
expressed in medullary carcinoma, while LPA1 was pre-
dominant in PDC and AC, and LPA2 and LPA3 were pre-
dominant in PTC (Table 1 and Fig. 1).
When assessed according to the histologic subtype and 
BRAF V600E mutation status, ATX (p = 0.002), LPA1 
(p = 0.014), and LPA2 (p = 0.001) expression was different 
according to the histologic subtype, and the expression 
of ATX, LPA1, LPA2 and LPA3 (p < 0.001) was different 
according to BRAF V600E mutation status. ATX, LPA1, 
and LPA2 expression was higher in conventional type 
than in FVPTC, while PTC with BRAF V600E muta-
tion showed higher expression of ATX, LPA1, LPA2, 
and LPA3 than did PTC without BRAF V600E mutation 
(Table 2 and Fig. 2). 
In FC cases, expression of LPA1 was highest in mini-
mally invasive type (p = 0.004, Table  3). In PTC cases, 
a statistically significant positive correlation between 
proteins related to the ATX–LPA axis was shown in 
the following: LPA1 and ATX (r = 0.434, p < 0.001), 
LPA1 (S) and LPA1 (r = 0.187, p = 0.001), LPA2 and 
ATX (r = 0.459, p < 0.001), LPA2 and LPA1 (r = 0.591, 
p < 0.001), LPA2 and LPA1 (S) (r = 0.188, p = 0.001), LPA3 
and ATX (r = 0.193, p < 0.001), LPA3 and LPA1 (r = 0.318, 
p < 0.001), and LPA3 and LPA2 (r = 0.295, p < 0.001) 
(Table 4).
Correlations between clinicopathologic factors 
and expression of proteins related to the ATX–LPA axis 
in thyroid cancer
When correlations between the expression of proteins 
related to the ATX–LPA axis and clinicopathologic fac-
tors were analyzed, LPA2 expression was different 
according to the stromal type (p = 0.009) in PTC, and 
LPA1 expression was different according to the vascular 
invasion status in FC (p < 0.001). In PTC, desmoplastic 
type showed high expression of LPA2. LPA1 negativity 
was correlated with vascular invasion in FC (Fig. 3).
Impact of the expression of proteins related to the ATX–
LPA axis on prognosis of thyroid cancer
The impact of expression of proteins related to the ATX–
LPA axis on the prognosis of thyroid cancer was ana-
lyzed. As a result, ATX positivity (p = 0.005) and LPA1 
positivity (p = 0.014) were two factors that demonstrated 
correlation with shorter overall survival (Table  5 and 
Fig.  4) in univariate analysis. Multivariate Cox analysis 
showed that lymph node metastasis (hazard ratio: 5.978, 
95% confidence interval (CI) 1.339–26.69; p = 0.019) was 
an independent factor associated with shorter DFS, while 
age (≥ 45 years) (hazard ratio: 16.39, 95% CI 2.129–126.2; 
p = 0.007) was an independent factor associated with 
shorter OS (Table 6).
Discussion
We investigated the expression of proteins related to 
the ATX–LPA axis in thyroid cancer. First, ATX was 
more highly expressed in medullary carcinoma than in 
other subtypes. Previous studies have shown that ATX-
related protein expression was higher in thyroid cancer 
or metastatic thyroid cancer than in normal thyroid tis-
sue or benign thyroid neoplasm [9, 10], but there has 
not been any report published to date on ATX-related 
protein expression in thyroid medullary carcinoma. 
Page 4 of 9Shin and Koo  J Transl Med          (2019) 17:288 
Fig. 1 Expression of proteins related to the ATX–LPA axis in thyroid cancer. ATX is highly expressed in medullary carcinoma, as are LPA1 in PDC and 
AC and LPA2 and LPA3 in PTC
Table 2 Expression of proteins related to the ATX–LPA axis according to the histologic subtype of PTC
Italic values represent significance of p-value (p < 0.05)
Parameters Total
n = 338 (%)
Histologic subtype p-value BRAF V600E mutation status p-value
Follicular variant
n = 36 (%)
Conventional type
n = 302 (%)
No mutation
n = 102 (%)
Mutation
n = 238 (%)
ATX 0.002 < 0.001
 Negative 220 (65.1) 32 (88.9) 188 (62.3) 91 (89.2) 129 (54.7)
 Positive 118 (34.8) 4 (11.1) 114 (37.7) 11 (10.8) 107 (45.3)
LPA1 0.014 < 0.001
 Negative 169 (50.0) 25 (69.4) 144 (47.7) 88 (86.3) 81 (34.3)
 Positive 169 (50.0) 11 (30.6) 158 (52.3) 14 (13.7) 155 (65.7)
LPA1 (S) 0.609 0.380
 Negative 323 (95.6) 35 (97.2) 288 (95.4) 99 (97.1) 224 (94.9)
 Positive 15 (4.4) 1 (2.8) 14 (4.6) 3 (2.9) 12 (5.1)
LPA2 0.001 < 0.001
 Negative 191 (56.5) 30 (83.3) 161 (53.3) 86 (84.3) 105 (44.5)
 Positive 147 (43.5) 6 (16.7) 141 (46.7) 16 (15.7) 131 (55.5)
LPA3 0.150 < 0.001
 Negative 56 (16.6) 9 (25.0) 47 (15.6) 42 (41.2) 14 (5.9)
 Positive 282 (83.4) 27 (75.0) 255 (84.4) 60 (58.8) 222 (94.1)
Page 5 of 9Shin and Koo  J Transl Med          (2019) 17:288 
The possible mechanism for the high expression of 
ATX in thyroid medullary carcinoma is the JAK/
STAT3 pathway. In previous studies on breast cancer, 
activation of the JAK/STAT3 pathway was reported to 
increase the expression of ATX [12], which is suggested 
to represent a putative STAT3 target gene. Meanwhile, 
it has been reported that the JAK/STAT3 pathway is 
also activated in thyroid medullary carcinoma [13, 14]; 
consequently, it is only plausible that ATX expression 
is somehow associated with the JAK/STAT3 pathway. 
Our study showed that LPA1 was highly expressed in 
PDC and AC, and that LPA2 and LPA3 were similarly 
highly expressed in PTC. A previous study on thyroid 
cancer reported that LPA1 messenger RNA expression 
showed no difference among normal thyroid tissue, 
benign thyroid nodule, and thyroid cancer [15]. How-
ever, the study had included PTC and FC for thyroid 
cancer; therefore, its direct comparison with our study, 
which includes PDC and AC in addition to PTC and FC 
for thyroid cancer, is not possible. Separately, another 
previous study suggested CD97 as a dedifferentiation 
marker in thyroid cancer [16], the expression of which 
is reported to be correlated with LPA receptor in thy-
roid cancer [17]. Such a result is related with the high 
expression of LPA1 in PDC and AC in our study. LPA2 
Fig. 2 Expression of proteins related to ATX–LPA axis in TPC. ATX, 
LPA1, LPA2, and LPA3 expression is higher in conventional-type PTC 
than in FVPTC, and PTC with BRAF V600E mutation shows higher 
expression of those than does PTC without BRAF V600E mutation
Table 3 Expression of proteins related to the ATX–LPA axis 
according to histologic subtype of FC
Italic values represent significance of p-value (p < 0.05)
Parameters Total













n = 13 (%)
p-value
ATX 0.296
 Negative 102 (91.9) 54 (88.5) 35 (94.6) 13 (100.0)
 Positive 9 (8.1) 7 (11.5) 2 (5.4) 0 (0.0)
LPA1 0.004
 Negative 73 (65.8) 32 (52.5) 31 (83.8) 10 (76.9)
 Positive 38 (34.2) 29 (47.5) 6 (16.2) 3 (23.1)
LPA2 0.987
 Negative 85 (76.6) 47 (77.0) 28 (75.7) 10 (76.9)
 Positive 26 (23.4) 14 (23.0) 9 (24.3) 3 (23.1)
LPA3 0.792
 Negative 52 (46.8) 27 (44.3) 19 (51.4) 6 (46.2)
 Positive 59 (53.2) 34 (55.7) 18 (48.6) 7 (53.8)
Table 4 Correlation among  the  expression of  proteins 
related to the ATX–LPA axis in PTC
Italic values represent significance of p-value (p < 0.05)
Parameters ATX LPA1 LPA1 (S) LPA2
LPA1
 Correlation coefficient 0.434
 p-value < 0.001
LPA1 (S)
 Correlation coefficient 0.053 0.187
 p-value 0.330 0.001
LPA2
 Correlation coefficient 0.459 0.591 0.188
 p-value < 0.001 < 0.001 0.001
LPA3
 Correlation coefficient 0.193 0.318 0.019 0.295
 p-value < 0.001 < 0.001 0.731 < 0.001
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has been previously reported to be highly expressed 
in PTC, which is in concordance with our results [15]. 
On the other hand, our study showed low expres-
sion of proteins related to the ATX–LPA axis in PTC 
and FVPTC without BRAF V600E mutation, a result 
that disagreed with those of the previous study that 
reported that ATX protein expression is not correlated 
with BRAF mutation status [9]. Usually, most FVPTC 
cases do not harbor BRAF V600E mutation; thus, it 
is necessary to assess the correlation between BRAF 
V600E mutation and the ATX–LPA axis. The most 
plausible mechanism is that BRAF V600E mutation 
activates cytokine release, which in turn increases 
ATX protein expression. Tumor cells showing BRAF 
V600E mutation tend to have increased cytokine secre-
tion such as that of interleukin (IL)-1β, IL-6, and IL-8 
[18], because cytokines such as tumor necrosis factor 
alpha or IL-1β increase ATX and LPA levels. In our 
study, ATX and LPA1 expression was a poor prognosis 
factor in PTC, which is in concordance with previous 
study results that had identified ATX as a poor prog-
nosis factor in breast cancer [19] and in prostate cancer 
[20] and, separately, LPA2 as a poor prognosis factor in 
breast cancer [21].
Fig. 3 Correlations between the clinicopathologic factors and the expression of proteins related to the ATX–LPA axis in thyroid cancer. When 
assessed according to tumor stomal type, desmoplastic type PTC shows high expression of LPA2. In FC, vascular invasion is correlated with LPA1 
negativity
Table 5 Univariate analysis of the influence of the expression of proteins related to the ATX–LPA axis in thyroid papillary 
cancer on disease-free and overall survival by the log-rank test
Italic values represent significance of p-value (p < 0.05)
Parameter Number of patients/
recurrence/death
Disease-free survival Overall survival
Mean survival (95% CI) 
months




 Negative 220/12/8 106 (103–109) 109 (107–111)
 Positive 118/6/10 104 (101–108) 102 (98–106)
LPA1 0.670 0.014
 Negative 169/10/4 106 (103–109) 110 (109–112)
 Positive 169/8/14 107 (104–110) 105 (101–108)
LPA1 (S) 0.156 0.909
 Negative 323/16/17 107 (105–109) 108 (106–109)
 Positive 15/2/1 96 (79–113) 102 (89–116)
LPA2 0.947 0.316
 Negative 191/10/8 107 (104–110) 108 (106–111)
 Positive 147/8/10 106 (103–110) 106 (103–110)
LPA3 0.209 0.204
 Negative 56/1/1 108 (104–111) 108 (106–111)
 Positive 282/17/17 106 (103–109) 107 (105–109)
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The clinical implication of our study is that the 
ATX–LPA signaling axis may be a possible therapeutic 
target in thyroid cancer. Ki16425, a nonlipid competi-
tive inhibitor of LPA1 and LPA3, actually suppressed 
bone metastasis in a mouse model [22]. Debio0719, an 
R-stereoisomer of Ki16425, was found to inhibit distant 
metastasis [23, 24]. BrP-LPA, which is a dual ATX and 
pan-LPAR inhibitor, inhibited cell migration and inva-
sion [25]. In addition, an ATX inhibitor, ONO-843050, 
decreased tumor volume to 50% to 60% in a mouse 
model of PTC [9]. Therefore, the ATX–LPA axis may 
be an effective treatment target for thyroid cancer, and 
further clinical trials are necessary.
Fig. 4 The impact of the expression of proteins related to the ATX–LPA axis on prognosis in thyroid papillary carcinoma. In univariate analysis, 
factors that are correlated with shorter overall survival in PTC are ATX positivity a and LPA1 positivity b 
Table 6 Multivariate analysis of factors influencing survival of patients with PTC
Italic values represent significance of p-value (p < 0.05)
Included parameters Disease-free survival Overall survival
Hazard ratio 95% CI p-value Hazard ratio 95% CI p-value
Age (years) 0.617 0.007
 < 45 versus ≥ 45 1.282 0.485–3.389 16.39 2.129–126.2
Sex 0.508 0.925
 Male versus female 0.700 0.244–2.011 1.065 0.290–3.915
Tumor size (cm) 0.816 0.188
 ≤ 2.0 versus > 2.0 1.134 1.134–3.268 2.005 0.711–5.653
Tumor extension 0.378 0.440
 Intrathyroidal versus extrathyroidal 0.641 0.239–1.722 0.647 0.214–1.955
LN metastasis 0.019 0.064
 No versus yes 5.978 1.339–26.69 2.940 0.939–9.202
ATX 0.997 0.360
 Negative versus positive 0.998 0.334–2.981 1.633 0.571–4.665
LPA1 0.688 0.252
 Negative versus positive 0.805 0.278–2.327 2.093 0.592–7.403
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Conclusion
The expression of proteins related to the ATX–LPA axis 
is different according to tumor subtype and is nota-
bly higher in metastatic thyroid cancer than in primary 
tumor. Furthermore, proteins related to the ATX–LPA 
axis may represent candidates for effective treatment tar-
get in thyroid cancer.
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